PubMed Health⌕ Search

Biomedical subjects

M Grigorescu

Publications and source records attributed to M Grigorescu.

At least 19 recordsLinked to original sources
PubMed1978

Metabolism of bile acids by strains of Acinetobacter anitratum and Acinetobacter lwoffii.

The activity of two species of bacteria: Acinetobacter anitratum and Acinetobacter lwoffii, isolated from jejunum of patients with achlorhydria and Reichel-Polya resection towards bile salts was investigated. These species were not previously tested from this view point. All strains tested hydrolyzed bile salts; conjugates of deoxycholic acid were hydrolyzed more readily than those of cholic acid. This feature may be used as a bacteriological taxonomic criterion.

Acinetobacter↗
PubMedDate not supplied

The outpatient management of peripheral diabetic neuropathy.

Diabetic neuropathy is a common complication of diabetes. Its commonest form is the bilateral, distal sensorimotor neuropathy and this has been associated with increased risk of disability from foot ulceration, inadvertent injury leading to gangrene as well as to amputation. The economic implications of the treatment of diabetic neuropathy and its consequences are enormous. In spite of this, there is no universally accepted method of treating it and efforts are still underway to find an adequate form of therapy. The following is a review of the outpatient management of peripheral diabetic neuropathy.

Ambulatory Care↗
PubMedDate not supplied

[Nifedipine pharmacokinetics in liver cirrhosis patients after the administration of a single oral dose].

The niphedipine pharmacokinetics was investigated in the patients with hepatic cirrhosis, in comparison with a group of healthy subjects, after administering unique doses of 10 mg per os. The niphedipine concentrations in serum were determined by a gas chromatography method. The niphedipine pharmacokinetics may be described in correspondence with the open pharmacokinetic model. The values of pharmacokinetic parameters of niphedipine in the patients with hepatic cirrhosis are significantly modified in comparison with those noticed in the healthy subjects. An increase in the level of the maximum concentrations (158 ng/ml versus 68 ng/ml), of the biological half time (11.9 hours versus 2.5 hours) and of the area under the curve of the drug concentrations in time (450 ng.ml-1.hour versus 205 ng.ml-1.hour) were found. The relative bioavailability [correction of biodisponibility] of niphedipine was double in the patients with hepatic cirrhosis versus the healthy subjects. The modified pharmacokinetics of niphedipine in the patients with hepatic cirrhosis and the great individual variations found, require a decrease of the dose in this category of patients and a surveillance of the clinical effect.

Administration, Oral↗